Vazquez de las Heras, IvonnePapaleo, NataliaGarcía, EugeniaSalido Galeote, MartaSalar Silvestre, AntonioHernández Llodrà, SilviaCalvo Gonzalo, XavierColomo Saperas, Luis Alberto2020-05-282020-05-282020Vazquez I, Papaleo N, García E, Salido M, Salar A, Hernandez S. et al. Clinical interest of LMO2 testing for the diagnosis of aggressive large B-Cell lymphomas. Cancers (Basel). 2020 Apr 5; 12(4):884. DOI: 10.3390/cancers120408842072-6694http://hdl.handle.net/10230/44836MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.application/pdfengCopyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/cancers12040884LMO2MYC rearrangementImmunohistochemistryLarge B-cell lymphomainfo:eu-repo/semantics/openAccess